Contact us | Add to favorites | Association address | Related link
Welcome to 2023/10/28 5:20:51
homepage About the Association Association dynamics Policies and regulations Beijing Medicine Express Industry dynamics International information Economic analysis Thematic discussion At your service Training registration Branch garden Social organization
Job column
  Current Location:首页>>Beijing Medicine Express>>Beijing Medicine Express
On the news broadcast of the disruptive technology competition, the art of Shenzhou won the highest prize

      From February 21 to 24, 2023, hosted by the Ministry of Science and Technology, hosted by the Torch Center of the Ministry of Science and Technology, and hosted by the Zhejiang Provincial Department of Science and Technology and the Hangzhou Municipal People's Government, the finals of the 2022 National Disruptive Technology Innovation Competition (referred to as the "Competition") were held in Hangzhou。On the opening day of the finals, CCTV's "News Broadcast" column carried out a news report on the event for the first time。

     Dr. He Ting, CEO of Beijing Yimiao Shenzhou Medical Technology Co., LTD. (referred to as "Yimiao Shenzhou"), participated in the competition with the cutting-edge CAR T cell technology project developed by the company,With the subversive and revolutionary advantages shown in the field of cell therapy technology,It has great clinical potential and broad application prospect,Stood out from 157 outstanding entries across the country,It was unanimously recognized by the live judges,Won the highest award in the finals - Winner's prize,And was recommended to enter the disruptive technology candidate library of the Ministry of Science and Technology。
Previously, as a key project of the unveiling list, Yimiao Shenzhou participating projects were directly nominated for the finals of the 2022 National Disruptive Technology Innovation Competition by the Beijing Municipal Science and Technology Commission and the Zhongguancun Science Park Management Committee。

       据悉,举办全国颠覆性技术创新大赛,是贯彻落实党的二十大精神和习近平总书记关于科技创新重要论述的重要举措。Wu Zhaohui, a member of the Party group and vice minister of the Ministry of Science and Technology, said in a video message,The holding of the contest,It aims to create an atmosphere of disruptive technological innovation,Fostering a culture of disruptive innovation,Explore the innovation mechanism of "discovery-selection-cultivation" of disruptive technologies,Discover and exploit a number of disruptive technology directions,Promoting disruptive technological innovation and breakthroughs,To provide a powerful engine for high-level scientific and technological self-reliance and high-quality economic development。

      Since its launch in July 2022, the competition has attracted more than 2,800 technical projects from key universities, well-known scientific research institutes, industry leading enterprises and other units across the country。After the preliminary screening of projects and field competitions, 157 high-quality projects with subversive potential were identified and selected to advance to the finals。
The competition focuses on technology fields that may produce major disruptive breakthroughs, such as integrated circuits, artificial intelligence, future networks and communications, biotechnology, new materials, green technology, high-end equipment manufacturing, and cross-disciplines,It has laid a solid foundation for cultivating global leading enterprises, reshaping industrial competition pattern, promoting future industrial development, and creating a strong atmosphere of disruptive innovation。

       Founded in 2015 and headquartered in Beijing, with the mission of "making cancer no longer a terminal disease", Yimio is committed to applying innovative gene cell drug technology to the treatment of malignant tumors, and has completed 9 rounds of strategic financing up to now。The company has a one-stop autonomous gene cell drug research and development and industrialization platform,Master the core technologies of large-scale plasmid preparation, lentiviral vector preparation, and primary immune cell preparation,Obtained 3 clinical trial approval notices issued by the State Drug Administration and Beijing's first gene cell drug "Drug Production License",The R&D pipeline covers blood tumors such as lymphoma, leukemia, myeloma, and solid tumors such as liver cancer, colorectal cancer, stomach cancer, and pancreatic cancer,It has become a leading innovation platform in the field of autonomous gene cell drugs in China。
      The company has been approved by the National Ministry of Science and Technology key research and development plan special project, Beijing Major science and technology special project and post-doctoral research workstation, national high-tech enterprise, Beijing specialized and special new enterprise, Zhongguancun Frontier technology Enterprise, Zhongguancun high-tech enterprise and other government projects and qualifications;The management team of the company has won the government honors such as Beijing Science and Technology Star, Zhongguancun High-end Leading Talent, Beijing Haiying Talent, New Gate Leading talent and so on。


(2023/3/3 9:54:30 Read 10742 times)

Beijing Pharmaceutical Industry Association public number

Copyright 2003-2016 percentred by Beijing Pharmaceutical Professiion Association All Rights Reserved
Copyright Beijing Pharmaceutical Industry Association. All rights reserved
ICP record number: Beijing ICP No. 11016038-1